Abstract
Plasma nicotine concentrations following administration by two types of nasal nicotine spray were compared in ten subjects. Absorption was particularly rapid during the first 2.5 min, the average rise in blood nicotine concentrations during this time being 8.6 ng/ml for the two products, followed by a small further rise to an average peak increase of 10.5 ng/ml 5 min after the dose of 2 mg nicotine base (mean 27.8 µg/kg). Despite a four-fold Cmax variation between subjects, the levels of individual subjects were fairly consistent across the two products. There were no significant differences between the two products in blood nicotine concentrations or cardiovascular responses, and the correlation between the AUCs from the two products was 0.68 (P=0.01). Eight subjects reported subjective feelings of light-headedness or slight dizziness, which are not typical after slower absorption from nicotine gum or skin patches. Blood nicotine levels within the smoking range were soon built up with repeated doses, even in the subject with the least efficient nasal absorption. In a second study of ad libitum use under clinical conditions both products appeared sufficiently acceptable for therapeutic use as an aid to smoking cessation. There was no tendency to escalate to excessive use over 4 weeks, and blood nicotine concentrations in nine subjects averaged only 44% of their prior smoking levels. Only one subject had levels equivalent to prior smoking and possible reasons why this was not more common are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abelin T, Muller P, Buehler A, Versanen K, Imhof PR (1989) Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet 1:7–10
Benowitz NL, Jacob P, Jones RT, Rosenberg J (1982) Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 221:368–372
Benowitz NL, Jacob P, Savanapridi C (1987) Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther 41:467–473
Benowitz NL, Porchet H, Sheiner L, Jacob P (1988) Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 44:23–28
Dubois JP, Sioufi A, Muller P, Mauli D, Imhof PR (1989) Pharmacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administration of different doses of transdermal nicotine systems. Methods Find Exp Clin Pharmacol 11:187–195
Feyerabend C, Russell MAH (1990) A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. J Pharm Pharmacol 42:450–452
Feyerabend C, Ings RMJ, Russell MAH (1985) Nicotine pharmacokinetics and its application to intake from smoking. Br J Clin Pharmacol 19:239–247
Gross J, Stitzer ML (1989) Nicotine replacement: ten-week effects on tobacco withdrawal symptoms. Psychopharmacology 98:334–341
Hajek P (1989) Withdrawal-oriented therapy for smokers. Br J Addict 84:591–598
Henningfield JE, Miyasato K, Jasinski DR (1985) Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 234:1–12
Herxheimer A, Griffiths RL, Hamilton B, Wakefield M (1967) Circulatory effects of nicotine aerosol inhalations and cigarette smoking in man. Lancet ii:754–755
Holm H, Jarvis MJ, Russell MAH, Feyerabend C (1992) Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology 108:507–511
Isaac PF, Rand MJ (1969) Blood levels of nicotine and physiological effects after inhalation of tobacco smoke. Eur J Pharmacol 8:265–283
Jarvis MJ, Russell MAH (1989) Treatment for the cigarette smoker. Int Rev Psychiatry 1:139–147
Jarvis MJ, Raw M, Russell MAH, Feyerabend C (1982) Randomised controlled trial of nicotine chewing gum. BMJ 285:537–540
Jarvis MJ, Hajek P, Russell MAH, West RJ, Feyerabend C (1987) Nasal nicotine solution as an aid to cigarette withdrawal: a pilot clinical trial. Br J Addict 82:983–988
Johansson CJ, Olsson P, Bende M, Carlsson T, Gunnarsson PO (1991) Absolute bioavailability of nicotine applied to different nasal regions. Eur J Pharmacol 41:585–588
Lam W, Sze PC, Sacks HS, Chalmers TC (1987) Meta-analysis of randomised controlled trials of nicotine chewing gum. Lancet ii:27–29
Matthews JNS, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. BMJ 300:230–235
McNabb ME (1984) Chewing gum for 3 months: what happens to plasma nicotine levels? Can Med Assoc J 131:589–592
Mulligan SC, Masterson JG, Devane JG, Kelly JG (1990) Clinical and pharmacokinetic properties of a transdermal nicotine patch. Clin Pharmacol Ther 47:331–337
Newman SP, Moren F, Clarke SW (1987) The nasal distribution of metered dose inhalers. J Laryngol Otol 101:127–132
Perkins KA, Epstein LH, Jennings JR, Stiller R (1986) The cardiovascular effects of nicotine during stress. Psychopharmacology 90:373–378
Perkins KA, Epstein LH, Stiller RL, Marks BL, Jacob RG (1989) Chronic and acute tolerance to the heart rate effects of nicotine. Psychopharmacology 97:529–534
Porchet HC, Benowitz NL, Sheiner LB (1988) Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther 244:231–236
Rand MJ (1989) Neuropharmacological effects of nicotine in relation to cholinergic mechanisms. In: Nordberg A, Fuxe K, Holmstedt B, Sundwall A (eds) Progress in brain research 79. Elsevier, Amsterdam, pp 3–11
Raw M, Jarvis MJ, Feyerabend C, Russell MAH (1980) Comparison of nicotine chewing gum and psychological treatments for dependent smokers. BMJ 281:481–482
Roth GM, McDonald JB, Sheard C (1944) The effect of smoking cigarettes. JAMA 125:761–767
Russell MAH (1988) Nicotine replacement: the role of blood nicotine levels, their rate of change, and nicotine tolerance. In: Pomerleau OF, Pomerleau CS (eds) Nicotine replacement: a critical evaluation. Liss, New York, pp 63–94
Russell MAH, Jarvis MJ, Feyerabend C (1980) A new age for snuff? Lancet i:474–475
Russell MAH, Jarvis MJ, Devitt G, Feyerabend C (1981) Nicotine intake by snuff users. BMJ 283:814–817
Russell MAH, Jarvis MJ, Feyerabend C, Ferno O (1983) Nasal nicotine solution: a potential aid to giving up smoking. BMJ 286:683–684
Russell MAH, Jarvis MJ, Jones G, Feyerabend C (1990) Nonsmokers show acute tolerance to subcutaneous nicotine. Psychopharmacology 102:56–58
Srivastava ED, Russell MAH, Feyerabend C, Masterson JG, Rhodes J (1991) Sensitivity and tolerance to nicotine in to smokers and nonsmokers. Psychopharmacology 105:63–68
Tonnesen P, Norregaard J, Simonsen K, Sawe U (1991) A doubleblind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 325:311–315
US Department of Health and Human Services (1988) Nicotine addiction: a report of the Surgeon General. Washington, DC
West RJ (1984) Psychology and pharmacology in cigarette withdrawal. J Psychosom Res 28:379–386
West RJ, Jarvis MJ (1986) Effects of nicotine on finger tapping rate in non-smokers. Pharmacol Biochem Behav 25:727–731
West RJ, Russell MAH (1987) Cardiovascular and subjective effects of smoking before and after 24 h abstinence from cigarettes. Psychopharmacology 92:118–121
West RJ, Jarvis MJ, Russell MAH, Feyerabend C (1984) Plasma nicotine concentrations from repeated doses of nasal nicotine solution. Br J Addict 79:443–445
West RJ, Hajek P, Belcher M (1987) Time course of cigarette withdrawal symptoms during four weeks of treatment with nicotine chewing gum. Addict Behav 12:199–203
West R, Hajek P, Belcher M (1989) Time course of cigarette withdrawal symptoms while using nicotine gum. Psychopharmacology 99:143–145
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sutherland, G., Russell, M.A.H., Stapleton, J. et al. Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology 108, 512–518 (1992). https://doi.org/10.1007/BF02247430
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02247430